Bill Gates Shares Plan To Tackle The ‘World’s Deadliest Animal’
Microsoft Corporation (NASDAQ: MSFT) co-founder Bill Gates shared a plan to outsmart the “world’s deadliest animal” on Monday.
Recap Of Monday’s Biotech Catalysts – End Of the Day Summary
Gritstone bio (NASDAQ:GRTS) announced that interim results from the Phase 1/2 trial of GRANITE, its individualized, vaccine-based immunotherapy…
Why Accelerate Diagnostics Shares Are Trading Higher Today
Becton Dickinson and Co (NYSE:BDX) will sell Accelerate Diagnostics Inc’s (NASDAQ:AXDX) rapid testing solution for antibiotic resistance and susceptibility, offering results in…
Why IDEAYA Biosciences Shares Plunging Today
Earlier today, IDEAYA Biosciences Inc (NASDAQ:IDYA) reported Q2 results, and shares have plunged 30% after the update. Investors are probably reacting…
Boston Scientific Adds ‘Novel’ Technology Via This Acquisition For Interventional Oncology
Boston Scientific Corporation (NYSE:BSX) has acquired privately-held Obsidio Inc that developed the Gel Embolic Material (GEM) technology to embolize blood vessels in the…
ContraFect Cuts Workforce After Trial Setback
ContraFect Corporation (NASDAQ:CFRX) said it continues to advance lead programs toward new clinical studies and expects to file with regulatory authorities…
FDA Clears Organogenesis’ Next Generation PuraPly Surgical Solution
Organogenesis Holdings Inc (NASDAQ:ORGO) has received the FDA 510k Clearance for PuraPly MZ, a brand extension to the PuraPly product portfolio. …
Horizon Therapeutics Inks Option Agreement For Atopic Dermatitis Candidate
Q32 Bio and Horizon Therapeutics plc (NASDAQ:HZNP) entered into a collaboration and option agreement to develop ADX-914 for autoimmune diseases. ADX-914 is…
Is Moderna Preparing To Soar 20% And Tackle This Big Level? What To Watch On The Weekly Chart
Moderna, Inc (NASDAQ: MRNA) spiked up almost 5% off Friday’s closing price at one point on Monday, before hitting a resistance level at the $179 level and running into a group of sellers.
BZ Chart Of The Day: Johnson & Johnson Is Nearing This Key Support Level
Johnson & Johnson (NYSE: JNJ) stock is oversold and getting close to a level that has been support in the past.
Oversold refers to momentum. It means the stock has been aggressively sold so hard that it is below what would be its usual or typical trading range.